OncoMatch/Clinical Trials/NCT04162353
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Is NCT04162353 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies BCMA-CD19 cCAR T cells for multiple myeloma in relapse.
Treatment: BCMA-CD19 cCAR T cells — This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Non-Hodgkin Lymphoma
Prior therapy
Must have received: standard therapeutic options
Patients have exhausted standard therapeutic options
Cannot have received: BCMAxCD3 or CD19xCD3 bispecific antibody
Prior treatment with BCMAxCD3 or CD19xCD3 bispecific agents
Cannot have received: solid organ transplantation
Prior solid organ transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify